Title
Category
Credits
Event date
Cost
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, participants should be able to:
  • S.U.D
  • Women's Health
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objectives:After this course, participants should be able to:
  • S.U.D
  • 0.75 AAFP Prescribed
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • 0.50 AAFP Prescribed
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options.Learning Objective:At the end of this session, learners should be able to:
  • Trauma-Informed Care
  • 20.00 AAFP Prescribed
  • 20.00 AMA PRA Category 1 Credit™
$0.00
Adverse Childhood Experiences (or ACEs) are associated with some of the most common, serious, and intractable health conditions facing our patients. Toxic stress from ACEs such as poverty, violence, and emotional or physical abuse can cause wear and tear on all body systems. In fact, ACEs are associated with increased risk for heart disease, cancer, accidents, respiratory disease, stroke, diabetes, kidney disease, and suicide.
  • S.U.D
  • 1.25 AAFP Prescribed
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 AOA Category 2-A
$0.00
This activity is part of CAFP's California Residency Program Collaborative around improving education, outreach and treatment for patients with substance use disorder disease, including stimulants and opioids, with a focus on medication assisted treatment options. Learning Objectives:At the end of this session, learners should be able to:
  • S.U.D
  • Pain Management
  • 3.00 AAFP Prescribed
  • 3.00 AMA PRA Category 1 Credit™
$0.00
The curriculum, Pain Management and Opioids: Balancing Risks and Benefits, meets the latest FDA Blueprint and CDC guidelines for opioid prescribing and pain management, and includes the impact of COVID-19, new pain relieving treatments, and telehealth. This education includes California state-specific information and counts towards California CME requirements for pain management and opioid prescribing practices.This activity meets the new DEA CME requirement when renewing or obtaining your DEA license.
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
People with substance use disorders (SUD) are coming to the office, whether we know it or not. Let's treat SUD/OUD (opioid use disorder) as we would treat any other medical condition: with compassion and good medicine. In this webinar you’ll learn to recognize stigma, communicate more effectively, and be more confident in choosing Medication for OUD (MOUD). Addiction medicine is family medicine.Learning Objective:At the end of this session, learners should be able to:Identify common barriers to health care practitioners beginning MOUD
  • S.U.D
  • 1.00 AAFP Prescribed
  • 1.00 AMA PRA Category 1 Credit™
$0.00
While gains have been made in reducing stigma around certain conditions, like depression and obesity, little progress has been made in removing the stigma around substance use disorders. The public and even health care providers continue to blame patients for their disease even though there is clear consensus that addiction is a complex brain disorder and not the result of moral weakness and flawed character.When people with addiction are stigmatized and rejected, especially by those within healthcare, it only contributes to the vicious cycle that entrenches their disease.

Pages